alogliptin
Sign in to saveAlso known as Nesina®, SYR-322, Vipidia®, Alogliptinum, Alogliptine, Alogliptina
Alogliptin, sold under the brand names Nesina and Vipidia, is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in people whose diabetes cannot adequately be controlled with metformin alone.
Research
680 papers- Alogliptin.2006
- Alogliptin.2012
- Alogliptin.2026
- Alogliptin-Associated Angioedema: Case Report and Review of the Literature.American journal of therapeutics · 2022
- [Alogliptin].Nihon rinsho. Japanese journal of clinical medicine · 2011
via PubMed
Wikidata facts
- Mass
- 339.17
Show 7 more facts
- chemical formula
- C₁₈H₂₁N₅O₂
- isomeric SMILES
- CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCC[C@H](C3)N
- canonical SMILES
- CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N
- World Health Organisation international non-proprietary name
- alogliptin
- Commons category
- Alogliptin
- defined daily dose
- 25
- melting point
- 181
Sources (6)
via Wikidata · CC0
~4 min read
Article
5 sectionsContents
- Medical uses
- Side effects
- Market access
- References
- External links
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 454952697 | image = Alogliptin.svg | image_class = skin-invert-image | alt =
| pronounce = | tradename = Nesina, VipidiaKazano, Vipidomet (with metformin)Oseni, Incresync (with pioglitazone) | Drugs.com = | MedlinePlus = a613026 | licence_EU = yes | DailyMedID = Alogliptin | licence_US = | pregnancy_AU = B3 | pregnancy_AU_comment = | pregnancy_US = B | pregnancy_US_comment = | pregnancy_category = | routes_of_administration = By mouth | ATC_prefix = A10 | ATC_suffix = BH04